MINNETONKA, Minn., Aug. 15, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of two clinical studies using Uroplasty's Urgent® PC Neuromodulation System are scheduled to be presented at the International Continence Society meeting, August 29-September 2, 2011 in Glasgow, Scotland.
"These data from on-going clinical studies continue to demonstrate the long-term efficacy of percutaneous tibial nerve stimulation (PTNS) delivered via Urgent PC in the treatment of overactive bladder syndrome," said David Kaysen, President and CEO of Uroplasty. "The studies build on a growing body of evidence that validates the treatment protocol, usefulness with both young and elderly patients, and the durability of the improvements with continued PTNS therapy."
ICS PresentationsSUmiT Trial Outcomes: Clinical Insights into Percutaneous Tibial Nerve Stimulation, presented by Dr. Peter Sand, NorthShore University Health, Chicago, IL Demonstrated that results are consistent for patients regardless of age Demonstrated that improvement occurs throughout the series of 12 initial treatments, with more improvement occurring during treatments 7 through 12Treatment Interval Frequency of Percutaneous Tibial Nerve Stimulation: 18-Month Results from the STEP Study, presented by Dr. Kenneth Peters, William Beaumont Hospital, Royal Oak, MI Responders to the initial series of 12 treatments treated with regular PTNS therapy, on an average of once per month, sustained their improvements in voiding symptoms and Quality of Life measures throughout 18 months of therapy
About Uroplasty Uroplasty, Inc., headquartered in Minnetonka, Minnesota,